Is a
Funding Round attributes
Funding Type
Funded Company
Funding Round Amount (USD)
26,000,000
Announcement URL
Funding Round Date
September 12, 2024
Vironexis Biotherapeutics, focused on pioneering AAV-delivered T-cell immunotherapy, recently launched with $26 million in seed financing. The round was led by Drive Capital and Future Ventures, with additional backing from Moonshots Capital and Capital Factory. The funds will support the advancement of Vironexis’s first two oncology programs, including the initiation of a Phase 1/2 clinical trial for VNX-101 in late 2024. VNX-101 is set to become the first-ever clinical trial for AAV-delivered cancer immunotherapy, targeting CD19+ acute lymphoblastic leukemia. The company's innovative TransJoin™ platform underpins its pipeline of over 10 product candidates.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
